Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $6.68, demonstrating a -0.89% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily loss of 0.33%. Meanwhile, the Dow lost 0.22%, and the Nasdaq, a tech-heavy index, lost 0.56%.The biotechnology company's shares have seen an increase of 9.24% over the last month, surpassing the Medical sector's loss of 4.31% and the S&P 500's gain of 1.83%.Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. In that report, analysts expect Recursion Pharmaceuticals to post earnings of -$0.33 per share. This would mark year-over-year growth of 23.26%. In the meantime, our current consensus estimate forecasts the revenue to be $34.71 million, indicating a 229.65% growth compared to the corresponding quarter of the prior year.RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$1.58 per share and revenue of $76.68 million. These results would represent year-over-year changes of 0% and +72.02%, respectively.Any recent changes to analyst estimates for Recursion Pharmaceuticals should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Recursion Pharmaceuticals is currently sporting a Zacks Rank of #3 (Hold).The Medical - Drugs industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 78, finds itself in the top 31% echelons of all 250+ industries.The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.To follow RXRX in the coming trading sessions, be sure to utilize Zacks.com.Zacks Names #1 Semiconductor StockIt's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $803 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Recursion Pharmaceuticals, Inc. (RXRX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks